This is particularly relevant in the therapeutic prospective of cancer treatment since a new paradigm for modulating angiogenesis has emerged by targeting endothelial metabolism and not the angiogenic factors that have demonstrated some limits in the success of VEGF-targeted therapy. This evidence concerns the gene VEGFA and cancer.